Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

DeVore Adam D.; Hill C. Larry; Thomas Laine; Sharma Puza P.; Albert Nancy M.; Butler Javed; Patterson J. Herbert; Spertus John A.; Williams Fredonia B.; Duffy Carol I.; McCague Kevin; Hernandez Adrian F.; Fonarow Gregg C.

首页> 外文期刊>Circulation. Heart failure >Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

【24h】

Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

机译：与萨法利亚尔/缬沙坦使用的患者，提供者和实践特征在美国使用

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND: Current guidelines recommend sacubitril/valsartan for patients with heart failure with reduced ejection fraction, but the rate of adoption in the United States has been slow.

机译：背景：目前的指导原则推荐Sacubitril / Valsartan对心力衰竭的患者减少射入分数，但美国采用的采用率一直缓慢。

著录项

来源
《Circulation. Heart failure》 |2018年第9期|共9页
作者
DeVore Adam D.; Hill C. Larry; Thomas Laine; Sharma Puza P.; Albert Nancy M.; Butler Javed; Patterson J. Herbert; Spertus John A.; Williams Fredonia B.; Duffy Carol I.; McCague Kevin; Hernandez Adrian F.; Fonarow Gregg C.;
展开▼
作者单位

Duke Clin Res Inst 2400 Pratt St NP-8064 Durham NC 27705 USA;

Duke Clin Res Inst 2400 Pratt St NP-8064 Durham NC 27705 USA;

Duke Clin Res Inst 2400 Pratt St NP-8064 Durham NC 27705 USA;

Novartis Pharmaceut E Hanover NJ USA;

Cleveland Clin Cleveland OH 44106 USA;

Univ Mississippi Med Ctr Jackson MS 39216 USA;

Univ N Carolina Eshelman Sch Pharm Chapel Hill NC 27515 USA;

St Lukes Mid Amer Heart Inst Kansas City MO 64110 USA;

Mended Hearts Huntsville AL USA;

Novartis Pharmaceut E Hanover NJ USA;

Novartis Pharmaceut E Hanover NJ USA;

Duke Clin Res Inst 2400 Pratt St NP-8064 Durham NC 27705 USA;

Ronald Reagan UCLA Med Ctr Ahmanson UCLA Cardiomyopathy Ctr Los Angeles CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心脏、血管（循环系）疾病;
关键词
heart failure; patients; prescription drugs; registries;

机译：心力衰竭;患者;处方药;注册表;

相似文献

外文文献
中文文献
专利

1. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States [J] . DeVore Adam D., Hill C. Larry, Thomas Laine, Circulation. Heart failure . 2018,第9期

机译：与萨法利亚尔/缬沙坦使用的患者，提供者和实践特征在美国使用
2. Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States [J] . Adam D. DeVore, Larry Hill, Laine Thomas, Journal of cardiac failure . 2018,第8期

机译：与萨法利亚尔/瓦斯坦的患者和实践特征在美国使用
3. Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States [J] . Adam D. DeVore, Larry Hill, Laine Thomas, Journal of cardiac failure . 2018,第8期

机译：与萨法利亚尔/瓦斯坦的患者和实践特征在美国使用
4. Effect of Valsartan Combined with Hydrochlorothiazide in the Treatment of Patients with Hypertensive Heart Disease [C] . Jing Bai, Yan Wang 2019 International Conference on Biology, Chemistry and Medical Engineering（ 2019年国际生物、化学和医学工程会议（ICBCME 2019）论文集 . -1

机译：缬沙坦联合盐酸血氮杂化的影响治疗高血压心脏病患者
5. Influence of Patient and Provider Characteristics on the Overuse of Health Care Services [D] . Tong, Junliang. 2018

机译：患者和提供者特征对医疗服务过度使用的影响
6. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale trial design and baseline data [O] . PK Judge, R Haynes, WG Herrington, -1

机译：沙比特利/缬沙坦与厄贝沙坦在慢性肾脏疾病患者中的随机多中心先导研究：英国心脏和肾脏保护（HARP）-III—理据试验设计和基线数据
7. Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data. [O] . UK HARP-III Collaborative Group 2016

机译：沙比特比/缬沙坦与厄贝沙坦在慢性肾脏疾病患者中的随机多中心先导研究：英国心脏和肾脏保护（HARP）-III级标准，试验设计和基线数据。

Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States

摘要

著录项

相似文献

相关主题

期刊订阅